Achromatopsia Market Epidemiology Report 2025-2035: Pipeline Therapies, Drugs Sales, and Regional Outlook The report provides a detailed analysis of the current achromatopsia marketed drugs and ...

This paper aims to solve the problem that achromatopsia cannot distinguish or perceive the energy of different colours. The problem of the previous study was to focus on the sound transforming into ...

Aims To determine long-term safety and efficacy outcomes of a subretinal gene therapy for CNGA3-associated achromatopsia. We present data from an open-label, nonrandomised controlled trial ...

There are three main types of color blindness, also known as color vision deficiency. Keep reading to learn about the different types and their causes.

MeiraGTx's innovative gene therapies for ocular diseases & more are backed by strong clinical data and funding. Click here to find out why MGTX stock is a Buy.

Achromatopsia CNGA3 A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC-402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, The purpose of this study is to learn about a new ...

ATSN-101 is well tolerated 12 months after treatment, with no drug-related serious adverse events. Clinically significant improvements in retinal sensitivity were sustained in patients receiving the ...

Objective To study the clinical features and to identify the pathogenic mutations in Chinese patients with achromatopsia (ACHM). Design Fifteen patients from 10 unrelated families were included in ...

Contrary to the traditional understanding that this disorder remains stable, long-term structural changes were observed through spectral-domain optical coherence tomography (SD-OCT) imaging.

Several rare diseases make up the condition known as inherited retinal dystrophy. Learn about their causes, symptoms, and treatments.